Table 2.

Patient demographics and previous and current treatments for chronic ITP patients

Demographic	Value
IPF (n = 24)
Mean age, y (range)	42 (0.5-82)
Male, no. (%)	11 (46)
Previous treatment	16 (67)
Steroids, no. (%)
IVIG, no. (%)	15 (63)
Intravenous anti-D, no. (%)	14 (58)
Rituximab, no. (%)	10 (42)
Other agents,* no. (%)	9 (38)
Splenectomy, no. (%)	8 (33)
Comparison of A-IPF and glycocalicin (n = 17)
Mean age, y (range)	53 (31-81)
Males, no. (%)	8 (47)
Current treatment
TPO-A, no. (%)	9 (53)
Prednisone, no. (%)	2 (12)
IVIG, no. (%)	2 (12)
Prednisone and IVIG, no. (%)	1 (6)
Rigel R788, no. (%)	1 (6)
Danazol and MMF,† no. (%)	1 (6)
No treatment, no. (%)	1 (6)

^*Other agents included danazol, MMF, and azathioprine.

^†MMF indicates mycophenolate mofetil.